摘要
目的观察肝动脉插管化疗栓塞(TACE)联合三维适形放疗(3D—CRT)治疗原发性肝癌的疗效。方法对采用影像学联合甲胎蛋白标准确诊的原发性肝癌患者,选择其中不能手术切除的54例患者,先行TACE治疗1~3次,2~3周后行3D—CRT治疗,依据WHO肿瘤近期疗效报告标准判定近期疗效;根据3年内生存率评价远期疗效。观察联合治疗近期和远期疗效。结果54例患者均完成治疗,9例病情完全缓解(16.67%);26例部分缓解(48.15%);稳定7例(12.96%);进展4例(7.41%);死亡8例(14.81%)。患者治疗后均随访,最长者随访3年,1、2、3年生存率分别是85.19%(46/54)、62.96%(34/54)及35.19%(19/54)。结论对不能手术的原发性肝癌患者行TACE联合3D—CRT治疗,不但能够有效控制病情,而且副作用小,患者耐受性好。
Objective To evaluate the clinical efficacy of transcatheter arterial chemembolization (TACE) and three-dimensional conformal radiotherapy (3D-CRT) for primary hepatocellular carcinoma (PHC). Methods 54 patients with inoperable PHC confirmed by imaging and AFP were given sequence of treatment, namely, TACE was performed first, 1 -3 times, followed by 3D-CRT with an interval of about 2 3 weeks. Short-term efficacy ( according to WHO report) and long-term efficacy ( according to three-year survival rate) were observed after combined treatment. Results Of all 54 patients, 9 patients ( 16.67% ) achieved complete response ( CR), 26 had partial response ( PR), 7 ( 12.96% ) achieved stable disease ( SD), 4 (7.41%) were progressional disease (PD) , 8 ( 14.81% ) were dead. All patients were followed up and the longest follow-up period was 3 years. One, two, three-year survival rates were 85. 19% (46/ 54) ,62.96% (34/54) and 35.19% (19/54) respectively. Conclusions The newly combined modality of TACE and 3D-CRT resuhs in a good outcome, which increases the survival period of inoperable PHC patients as well as improves their quality of life, with little tolerable side-effects.
出处
《中华消化病与影像杂志(电子版)》
2013年第2期16-18,共3页
Chinese Journal of Digestion and Medical Imageology(Electronic Edition)
关键词
肝肿瘤
化学栓塞
治疗性
放射疗法
适形
Liver neoplasms
Chemoembolization, therapeutic
Radiotherapy, conformal